Increased Risk Of Bladder Cancer For Actos Users
Clinical research consistently demonstrates that a repeated undesirable result is the best predictor of future risk. This is a clear rationale for the case of Actos (pioglitazone), Takeda’s blockbuster diabetes drug...
